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INTRODUCTION
Polycystic Ovary Syndrome (PCOS) is the most
common endocrine disorder in women, occurring
in 5-7% of women in reproductive age.1 PCOS pa-
tients experience various clinical symptoms includ-
ing oligo- or amenorrhea with  infertility, a hyper-
androgenism condition manifested as hirsutism,
acne, androgenic alopecia, as well as systemic dis-
orders such as obesity, dyslipidemia, insulin resis-
tance and hyperinsulinism.2 The presence of these
systemic disorders places patients at a high risk for
diabetes mellitus and cardiovascular disorders.3
Abstract
Objective: To compare the Neuropeptide Y (NPY) levels in non-
obese Polycystic Ovary Syndrome (PCOS) patients without insulin re-
sistance and non-obese women without insulin resistance, in consid-
eration of the psychopathologic conditions occurring in PCOS pa-
tients as well as the influence of these changes in affecting NPY lev-
els.
Methods: The subject was fourteen PCOS patients and 20 non-obese
normal women, both without insulin resistance. The measurements
of blood NPY levels using the ELISA method and a psychology as-
sessment using Symptom Check List 90 (SCL-90) were carried out.
Statistical analysis was performed using SPSS 17.
Results: From 20 PCOS patients included in this study, 6 subjects
(30%) were detected as having psychopathologic problems through
completion of the SCL-90 questionnaire, with a cut-off score of >70
points. Measurement of NPY levels using ELISA found a mean NPY
level of 8.02 ± 3.92 (95% CI 2.39 - 18.66) in the PCOS group com-
pared to a mean of 7.78 ± 4.31 pg/ml (95% CI 0.74 - 15.47) in the
control group. No significant difference was found in the mean levels
of NPY between the two groups. Statistical assessment using the
Spearman 2-variable correlation test also found no significant corre-
lation between NPY levels and the SCL-90, scores in the PCOS group.
Conclusion: There was no significant difference in NPY levels between
the PCOS group and control group. Thirty percent of non-obese
PCOS patients without insulin resistance were identified as having
psychopathologic conditions. But in this group of patients, the psy-
chopathologic changes had no influence on the levels of blood NPY.
[Indones J Obstet Gynecol 2012; 36-3: 125-9]
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Abstrak
Tujuan: Membandingkan kadar NPY pada pasien Sindroma Ovarium
Poli Kistik (SOPK) nir-obese tanpa resistensi insulin dengan perem-
puan nir-obese tanpa resistensi insulin, dan mengetahui adanya kon-
disi psikopatologis yang terjadi pada penderita SOPK nir-obese tanpa
resistensi insulin, serta mengetahui pengaruhnya terhadap kadar NPY.
Metode: Dilakukan pemeriksaan kadar neuropeptida Y dalam darah
dengan metode ELISA dan penilaian kondisi psikologis dengan meng-
gunakan Symptom Check List 90 (SCL-90) pada empat belas sampel
penderita SOPK dan 20 perempuan normal nir-obese dan tanpa resis-
tensi insulin. Analisis statistik dilakukan dengan SPSS 17.
Hasil: Di antara 20 subjek penderita sindroma ovarium polikistik di-
dapatkan 6 subjek (30%) mengalami gangguan psikopatologi yang
terdeteksi melalui hasil pengisian kuesioner SCL 90 di mana pada
kelompok tersebut didapatkan hasil kuesioner >70. Dari pengukuran
kadar NPY dengan metode ELISA didapatkan rerata kadar NPY pada
kelompok penderita SOPK nir-obese dan tanpa resistensi insulin
adalah 8,02 pg/ml ± 3,92 (IK 95%; 2,39-18,66) dan 7,78 pg/ml ± 4,31
(IK 95%; 0,74-15,47) pada perempuan normal nir-obese tanpa resis-
tensi insulin. Tidak terdapat perbedaan bermakna pada rerata nilai
NPY pada kedua grup dengan nilai p>0,05. Dengan uji statistik kore-
lasi 2 variabel Spearman tidak didapatkan hubungan antara kadar NPY
dengan nilai SCL pada kelompok penderita SOPK, dengan nilai p>0,05.
Kesimpulan: Tidak terdapat perbedaan kadar NPY yang bermakna
antara kelompok SOPK nir-obese tanpa resistensi insulin dan perem-
puan normal nir-obese. Sekitar 30% penderita SOPK nir-obese tanpa
resistensi insulin mengalami kondisi psikopatologis dan kondisi psi-
kopatologis tidak berpengaruh terhadap kadar NPY pada penderita
SOPK nir-obese tanpa resistensi insulin.
[Maj Obstet Ginekol Indones 2012; 36-3: 125-9]
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In PCOS, a neuroendocrine disturbance occurs
in the form of increased gonadotropin releasing
hormone (GnRH) pulsatility, leading to a domi-
nance of luteinizing hormone (LH) secretion over
follicle stimulating hormone (FSH) secretion that
causes an elevation in the LH:FSH ratio.2 This in-
creased LH stimulation on the theca cells leads to
the occurrence of hyperandrogenism, further in-
tensified by insulin resistance.4
GnRH is secreted in a pulsatile fashion. Episodic
secretion of GnRH indicates the presence of intrin-
sic neuronal activity from the hypothalamus. Vari-
ous neurotransmitters influence GnRH secretion,
including GnRH itself, prolactin, norepinephrine,
galanin, β-endorphin, dopamine, and neuropeptide
Y.5 Other factors influencing secretion of GnRH in-
cludes angiotensin II, serotonin, neurotensin, so-
matostatin, corticotrophin releasing factor (CRF),
melantonin, oxytocin, and substance P.4
Neuropeptide Y (NPY) increases secretion of
GnRH through central action on the terminal axon
of GnRH in the mediobasal of hypothalamus and
increases the number of GnRH receptors in the go-
nadotrophic hypophysis.6 NPY is also an orexigenic
peptide that along with galanin, modulates the ap-
petite and holds an important role in the mecha-
nism of GnRH secretion.7
Barnowska et al found an elevation of NPY levels
in both obese and non-obese PCOS patients, al-
though the extent of elevation is not correlated to
the increase of body mass index (BMI).7 Mean-
while, Generelli et al reported similar NPY levels
between PCOS patients and normal ovulating wo-
men. They also observed a disturbance in counter-
regulatory responses towards hypoglycemia in re-
lation to NPY secretions in obese PCOS patients.8
Levels of NPY are influenced by the presence of
insulin resistance, leptin resistance, psychopatho-
logic conditions, cannabinoid substances, and ghre-
lin. Several studies have observed the psychopa-
thologic problems occurring in PCOS.9,10 Literatu-
res show that these psychopathologic problems
influence NPY secretion, and thus indirectly affect-
ing the GnRH secretion. There is a different physio-
logic response towards acute and chronic psycho-
pathologic conditions, while the psychopathology
in PCOS is generally chronic. The presence of psy-
chopathology could affect the quality of life and the
success of PCOS therapy.
Clomiphene citrate is commonly used for induc-
tion of ovulation in PCOS patients, while insulin re-
sistance is managed by administration of metfor-
min. In a study carried out by Imani et al, it was
found that 30% of PCOS patients did not show a
good response towards clomiphene citrate admini-
stration.11 Failure mainly occured in the non-obese
PCOS patient that did not have insulin resistance.
Therefore, more thorough research is needed re-
garding central factors in the pathophysiology of
PCOS that help increase success of therapy. Con-
sidering the various factors that could increase the
pulsatility of GnRH, including psychopathologic
conditions in PCOS patients, this study aims to de-
termine NPY levels in non-obese PCOS patients
without insulin resistance, as well as focusing on
psychopathologic condition of patients that could
potentially influence the pathophysiology of PCOS.
METHODS
The research was conducted in Department of Ob-
stetrics and Gynecology FKUI-RSCM from October
2011 to December 2011. We recruited 20 patients
with PCOS and 20 control subjects who underwent
psychopathologic examination using the SCL-90
questionnaire in Yasmin Kencana RSCM. The meas-
urement of NPY levels was performed by ELISA
method in Prodia Laboratory, Jakarta. All obtained
data were kept in a magnetic plate, before the cod-
ing and editing process were performed. A valida-
tion process was then conducted to correct con-
founding variables and data analysis was carried
out using SPSS 17. The comparison of NPY level was
analyzed using unpaired t-test; while the relation-
ship between NPY level and psychopathologic con-
dition was analyzed by Pearson correlation test.
RESULTS
The samples included in this study were comprised
of 20 subjects with PCOS and 20 subjects as con-
trols. Among the sample group of PCOS patients,
90% had primary infertility and 10% had secon-
dary infertility.
From 20 PCOS patients, we found that 6 subjects
(30%) had psychopathologic disorders detected
through the SCL-90 questionnaire, with the afore-
mentioned group scoring >70 points in the ques-
tionnaire. Data of these subjects were excluded in
further analysis comparing the study group and the
control group. Therefore, the number of subjects in
the PCOS group was only 14 subjects in further
analysis.
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Comparison of mean NPY levels in the study
group and control group showed no significant dif-
ference of the mean blood NPY levels with a p-
value of >0.05.
Table 1. Comparison of NPY levels in non-obese PCOS pa-
tients without insulin resistance and normal women with-
out insulin resistance
N Mean Standard
Deviation
p-
value*
NPY levels PCOS 14 8.0271 3.92867 0.868
Control 20 7.7840 4.31282
*p-value obtained using unpaired t-test
Table 2. Correlation of NPY levels with SCL-90 scores in
PCOS group and control group
Mean
NPY
SD Mean SCL-
90 Score
SD Corre-
lation
p-
value
PCOS
group
8.0271 3.928 31.79 19.56 0.225 0.439*
Control
Group
7.7840 4.312 14.35 14.354 -0.012 0.960**
  * p-value obtained using Pearson test
** p-value obtained using Spearman test
Table 3. The relationship of psychopathologic conditions
and event of PCOS
SCL-90 Category
p-value*
Normal Psychopathology
PCOS group 14 6 0.02
Control group 20 0
*p-value obtained using Fisher’s exact test
From the results of Fisher’s exact test, a p-value
<0.05 was obtained, and thus we can assume that
there is a relationship between the event of PCOS
and the presence of psychopathologic conditions.
DISCUSSION
In our study, we discovered that 30% of the total
study group with PCOS had psychopathologic con-
ditions that was not initially recognized by the pa-
tients and was detected using the SCL-90 question-
naire. A previous study by Elsenburch et al, which
evaluated the presence of emotional psycho-
pathologic conditions in PCOS patients using the
same questionnaire, found that 15.4% of PCOS pa-
tients in their sample had psychological disor-
ders.12 However, in the study by Elsenburch et al,
the identified psychopathologic conditions were
related to the increase in BMI. Meanwhile in this
study, all of our samples had a BMI of <25 kg/m2.
This is a new finding, where the occurrence of psy-
chopathologic conditions in PCOS patients is not al-
ways related to an increase in BMI but could also
occur in non-obese PCOS patients, and it might not
be recognized by the patients themselves as well
as their physician. The cause of psychopathologic
conditions in these non-obese PCOS patients could
not be determined as of now.
Baranowska et al conducted a study and found
elevated NPY levels in both obese and non-obese
PCOS patients. However, no significant relationship
was found between NPY and changes in LH levels
as a response to GnRH. Likewise, no significant re-
lationship was found between NPY and insulin.
Baranowska et al also found that the increment of
NPY was not proportionately related to increment
of BMI in non-obese PCOS patients. This study did
not observe a significant relationship between
NPY, insulin, and testosterone as well as the rela-
tionship between NPY levels and the percentage in-
crement of LH as a response towards GnRH.7
In this study, we found that the mean NPY level
in the sample group of non-obese PCOS patients
was 8.02 ± 3.92 pg/ml (95% CI 2.39 - 18.66 pg/ml),
while the mean level for the control group was 7.78
± 4.31 pg/ml (95% CI 0.74 - 15.47 pg/ml). How-
ever, statistical analysis using unpaired t-test
showed no significant difference between the two
groups (p>0.05). The samples and control group in
this study had a HOMA score of <2.5, which became
a cut-off point for the absence of insulin resistance.
The results of this study were not similar to the
findings of Baranowska et al since this study limits
the subjects to those who did not have insulin re-
sistance. In the study by Zaryevski et al, findings
showed that elevated NPY in the hypothalamus
would lead to hyperinsulinism and hypercorticism,
as well as enhanced lipoprotein lipase activity and
insulin resistance in muscles.13 This is consistent
with findings by Genarelli et al who found no sig-
nificant difference in the NPY levels of non-obese
PCOS patients in comparison with non-obese nor-
mal subjects,8 as was found in our study. Findings
by Genarelli et al showed that the lower levels of
NPY in the obese PCOS group was associated with
decreased sympathetic activity in the hypoglyce-
mic state after insulin administration.8
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From various literatures, it was known that the
presence of decreased insulin sensitivity in PCOS
patients is a secondary effect of disturbance in the
homeostasis of positive energy and abdominal fat
accumulation.14 Glucose homeostasis is maintained
through a complex mechanism involving multiple
factors and insulin.15 Several studies showed that
PCOS patients experienced a period of subnormal
glucose levels leading to increased caloric intake
stimulation. Counter regulatory mechanisms will
deal with this abnormal glucose state. However, in
obese PCOS patients, this counter-regulatory re-
sponse undergoes a disturbance and thus in these
patients, episodes of hypoglycemia is not followed
by increase in sympathetic activity and NPY levels
as encountered in non-obese PCOS patients. Mean-
while, in non-obese PCOS patients, no significant
difference in NPY levels was found compared to
non-obese normal subjects.8 The comparable levels
of NPY between the sample and control group was
caused by the absence of insulin resistance in non-
obese PCOS patients that comprise the sample
group.
Therefore, it can be concluded that NPY levels
are not correlated with the occurrence of increased
GnRH pulsatility in non-obese PCOS patients with-
out insulin resistance. However, further studies
evaluating NPY levels in non-obese PCOS patients
with insulin resistance is needed in order to un-
derstand the relationship between NPY levels and
increased pulsatility in non-obese PCOS patients
with insulin resistance.
In this study the trend of NPY levels was similar
between the samples and control group, especially
up to a cut-off point of 11 pg/ml. However, when
NPY levels exceed 11 pg/ml, the trend moves to-
wards the control group. The selection of controls
has been aimed at minimizing influencing factors
that may lead to increased NPY levels, such as pre-
sence of psychopathologic conditions, glucocorti-
coid consumption as well as use of narcotics and
illicit drugs. Literatures state that consumption of
sugar-rich food can increase secretion of NPY.16
Previous studies have also shown that there is an
increment of leptin concentration of up to 50%
during the late follicular and luteal phase, the
mechanism of which is assumed to be due to in-
creased leptin secretion by adipocytes as a re-
sponse towards increased caloric intake or NPY se-
cretion.17 In our study, during the time of blood
collection, the stage of menstrual cycle was not
taken into account. This may be the contributing
factor leading to high NPY levels in several subjects
in the control group.
As has been noted in previous studies, various
factors influence the pulsatility of GnRH. One influ-
ential factor is pro-opiomelanocortin (POMC). Neu-
rons producing POMC in the arcuate nucleus have
synapses with cells producing GnRH.18 POMC is a
peptide belong to the opioid class that has anor-
exigenic properties and inhibit GnRH secretion. It
has also been stated that there is an overlapping
intracellular signal pathway between leptin and in-
sulin that brings to question whether these signals
of leptin and insulin towards NPY and POMC plays
a role in the regulation of GnRH secretion. How-
ever, further studies are needed on leptin, insulin,
NPY and POMC, and their correlation that may af-
fect GnRH pulsatility.
In this study, we found that the mean NPY level
in a subgroup of non-obese PCOS patients without
insulin resistance who experience psychopatholo-
gic conditions was 7.60 ± 3.34 pg/ml (95% CI 3.37-
11.83). Meanwhile, the mean NPY levels in the
same group but who did not experience psychopa-
thology was 8.02 ± 3.92 pg/ml (95% CI 2.39-
18.66). Statistical analysis found no significant dif-
ference between the two subgroups. Furthermore,
Pearson correlation test in the control group found
no correlation between SCL-90 scores and NPY le-
vels, as was the fact in the PCOS group that were
analyzed using Spearman correlation test. This was
consistent with the study by Morgan et al, who
found that in acute psychopathologic state, there
was an increase in NPY levels that was positively
correlated with cortisol and norepinephrine secre-
tion.19 This elevation in NPY comprises a response
mechanism towards a psychopathologic state, whi-
ch could predict an individual’s ability to adapt to
the psychopathologic state.18 However, in chronic
and uncontrolled psychopathologic conditions, a
sympathetic dysregulation is present and causing
a decline in NPY response towards psychopatho-
logic conditions.20
From the findings in this study, we can assume
that the psychopathologic state in non-obese PCOS
patients without insulin resistance has no influence
on NPY levels in the pathophysiology of PCOS. Psy-
chopathologic condition is thought to have a direct
effect on increased GnRH pulsatility, therefore lea-
ding to an increase in the LH:FSH ratio, a common
event in PCOS.
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CONCLUSION
No significant difference found in the NPY levels of
non-obese PCOS patients without insulin resis-
tance in comparison with non-obese normal wo-
men. This study found that 30% of non-obese PCOS
patients without insulin resistance experience a
psychopathologic state, but this was found to have
no influence on the NPY levels on non-obese PCOS
patients without insulin resistance.
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